Nasdaq

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

BURLINGTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
Seeking Alpha

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 ...

Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone’s clinical ...
Reuters

Minerva Neurosciences falls as US FDA declines to approve drug for schizophrenia symptoms

Feb 27 (Reuters) - Minerva Neurosciences (NERV.O), opens new tab said on Tuesday the U.S. Food and Drug Administration (FDA) has declined to approve its drug to regulate behavioral changes in patients ...